Abstract:Abstract Background: The efficacy of current T cell-based immunotherapy is known to be limited by various factors that induce immune suppression in the tumor microenvironment (TME). Tumor-associated macrophages (TAMs) are representative TME-comprising immune suppressive cells and influence tumor growth and progression. TAMs are considered as an attractive target for cancer immunotherapy. However, current TAMs-targeting strategies are not sufficient to induce continuous antitumor responses. Here, we suggest a new strategy that can reprogram TAMs and further bridge innate-to-adaptive immunity by utilizing immunostimulatory CpG oligodeoxynucleotides (ODNs). In this study, we investigated the new role of TLR9 agonist CpG ODN as an immunotherapeutic agent and tested whether liposomal delivery of CpG could modulate the function of TAMs and lead to remodeling of the TME. Methods: A liposome-based nanomaterial encapsulating CpG ODN was constructed. A small lipid nanoparticle (SLNP) used as the CpG delivery platform in this study was made of a cationic cholesterol derivative and two biocompatible phospholipids. The CpG-encapsulating SLNP (SLNP@CpG) was prepared by a thin-film formation and rehydration method. In vitro studies were conducted to assess whether SLNP@CpG could reprogram macrophages. To assess antitumor therapeutic efficacy of the SLNP@CpG, two subcutaneous tumor models were established in mice and tumor growth and survival rates of mice were monitored. For tumor rechallenge experiment, mice showing complete tumor regression were rechallenged with same cancer cells and their splenocytes were analyzed to confirm the development of immune memory. To elucidate the immunological mechanism of SLNP@CpG-mediated antitumor efficacy, changes of immune cell subpopulations in treated tumors were analyzed by flow cytometry. Results: SLNP@CpG enhanced macrophage-mediated phagocytosis of cancer cells and tumor antigen cross-presentation, and skewed the polarization state of macrophages in vitro. Intratumorally injected SLNP@CpG exerted its therapeutic efficacy in an established E.G7-OVA tumor via uptake by TAMs. SLNP@CpG treatment significantly suppressed the E.G7 tumor growth and also considerably prolonged the survival of mice, with 83.3% of mice becoming tumor-free. Local administration of SLNP@CpG resisted E.G7 tumor rechallenge by inducing immunological memory and long-term antitumor immunity. Local administration of SLNP@CpG even exerted its antitumor efficacy in an aggressive B16-F10 melanoma by remodeling TME towards immune stimulation and tumor elimination. Conclusion: Liposomal delivery of CpG via local treatment reprogrammed TAMs by enhancing phagocytic activity and repolarizing M2 to M1 phenotype and also reshaped immunosuppressive TME, leading to antitumor immunity and long-term memory responses. Citation Format: Yujin Kim, Sangyong Jon. Liposomal Delivery of an Immunostimulatory CpG Induces Robust Antitumor Immunity and Long-Term Immune Memory by Reprogramming Tumor-Associated Macrophages. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5164.

Yeast β-Glucan-Grafted Glycogen Nanoparticles for Macrophage-Targeted Precise Delivery of CpG Oligodeoxynucleotides: Implications for Immunotherapy Applications

Aminated yeast β-D-glucan for macrophage-targeted delivery of CpG oligodeoxynucleotides and synergistically enhanced cancer immunotherapy

Glycogen for lysosome-targeted CpG ODNs delivery and enhanced cancer immunotherapy

pH-sensitive PEG-coated hyper-branched β-d-glucan derivative as carrier for CpG oligodeoxynucleotide delivery

Targeting Delivery Oligonucleotide into Macrophages by Cationic Polysaccharide from Bletilla Striata Successfully Inhibited the Expression of TNF-α

Yeast glucan particles: An express train for oral targeted drug delivery systems

Emerging nanoparticle platforms for CpG oligonucleotide delivery

Self-modifying NanoEnhancers Facilitating Lysosomal Escape for Cgas-Sting Cascading Activation in Tumor Immunotherapy

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

Engineering CpG‐ASO‐Pt‐loaded Macrophages (CAP@M) For Synergistic Chemo‐/Gene‐/Immuno‐Therapy

Abstract 5164: Liposomal Delivery of an Immunostimulatory CpG Induces Robust Antitumor Immunity and Long-Term Immune Memory by Reprogramming Tumor-Associated Macrophages

Targeted Delivery of Oligonucleotides into Tumor-Associated Macrophages for Cancer Immunotherapy

Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.

CpG Oligodeoxynucleotide-Coated Chitosan Nanoparticles Enhance Macrophage Proinflammatory Phenotype In Vitro

The Antitumor Efficacy of CpG Oligonucleotides is Improved by Encapsulation in Plant Virus‐Like Particles

Macrophage membrane-coated Eucommia ulmoides polysaccharides-loaded PLGA nanoparticles as an effective antigen-targeted delivery system

Exploiting Macrophages As Targeted Carrier to Guide Nanoparticles into Glioma

Efficient gene delivery by multifunctional star poly (β-amino ester)s into difficult-to-transfect macrophages for M1 polarization

Nanomaterial-assisted delivery of CpG oligodeoxynucleotides for boosting cancer immunotherapy

Yeast cell membrane-camouflaged PLGA nanoparticle platform for enhanced cancer therapy

Lipid Nanoparticle Delivery Alters The Adjuvanticity of The TLR9 Agonist Cpg by Innate Immune Activation in Lymphoid Tissue